Oppenheimer reiterates its "Outperform" rating on Gilead (GILD -0.2%), saying that the company has a number of under-appreciated opportunities related to its HIV combination treatments. Oppenheimer therefore reckons Gilead will generate more money from those medicines than expected.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Fri, 12:50PM)
at Benzinga.com (Wed, 3:29PM)
at Nasdaq.com (Feb 20, 2015)
at Benzinga.com (Feb 20, 2015)
at Investor's Business Daily (Feb 4, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs